Market Place
Sourcing Support
ImmunityBio Completes 100th Patient Enrollment in NMIBC CIS Trial
19 Nov 2024 //
BUSINESSWIRE
ImmunityBio Reports Third-Quarter 2024 Financial Results
12 Nov 2024 //
BUSINESSWIRE
First Patients Dosed In ImmunityBio’s CAR-NK Therapy Study
24 Oct 2024 //
BUSINESSWIRE
ImmunityBio Joins Jefferies London Healthcare Conference
21 Oct 2024 //
BUSINESSWIRE
ImmunityBio Reports NSCLC Survival Data, Plans Phase 3 Trials
09 Sep 2024 //
BUSINESSWIRE
Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers
05 Sep 2024 //
FIERCE PHARMA
ImmunityBio to Lay Off 16, Will Likely Need Additional Capital
04 Sep 2024 //
BIOSPACE
ImmunityBio`s ANKTIVA Covered By Plans Representing 100M+ Lives
12 Aug 2024 //
BUSINESSWIRE
ImmunityBio Studies ANKTIVA® With AdHER2DC For Endometrial Cancer
06 Aug 2024 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Gains Insurance Coverage, First Doses Administered
20 Jun 2024 //
BUSINESSWIRE
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
07 Jun 2024 //
BUSINESSWIRE
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
03 Jun 2024 //
BUSINESSWIRE
UroToday Podcast Explores ANKTIVA Triangle Offense With Dr Soon-Shiong
17 May 2024 //
BUSINESSWIRE
ImmunityBio Completes ANKTIVA Manufacturing For 170K Doses
07 May 2024 //
BUSINESSWIRE
ImmunityBio, Serum Institute In BCG Global Supply Arrangement
02 May 2024 //
BUSINESSWIRE
ImmunityBio`s Soon-Shiong To Discuss ANKTIVA® At AUA Conference
30 Apr 2024 //
BUSINESSWIRE
ImmunityBio`s Anktiva+CPI Shows Survival Benefit in NSCLC
25 Apr 2024 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Approved For BCG-Unresponsive Bladder Cancer
22 Apr 2024 //
BUSINESSWIRE
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial
21 Feb 2024 //
BUSINESSWIRE
ImmunityBio Snags $320M Royalty Deal Ahead of FDA Decision in April
02 Jan 2024 //
BIOSPACE
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
16 Nov 2023 //
BUSINESSWIRE
First Data for Immunity’s Cytokine-Enriched NK Cells in Small Cell Lung Cancer
07 Nov 2023 //
BUSINESSWIRE
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
26 Oct 2023 //
BUSINESSWIRE
ImmunityBio Announces Biological License Application Resubmission for N-803
23 Oct 2023 //
BUSINESSWIRE
Second layoff wave hits ImmunityBio in less than a year
22 Sep 2023 //
FIERCE BIOTECH
ImmunityBio Announces $470 Million Equity and Debt Financing From Dr. Patrick
11 Sep 2023 //
BUSINESSWIRE
ImmunityBio Names Enrique Diloné as Chief Technology Officer
03 Aug 2023 //
BUSINESSWIRE
ImmunityBio Announces Execution of $40M Equity Financing with Investors
20 Jul 2023 //
BUSINESSWIRE
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
22 May 2023 //
BUSINESSWIRE
ImmunityBio gets FDA snub on cancer drug, shares crash
12 May 2023 //
FIERCE PHARMA
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?
08 May 2023 //
FINANCE YAHOO
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Plus N-803
25 Apr 2023 //
BUSINESSWIRE
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong
24 Apr 2023 //
BUSINESSWIRE
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study
16 Feb 2023 //
BUSINESSWIRE
ImmunityBio Announces Execution of $50M Equity Financing with Investors
15 Feb 2023 //
BUSINESSWIRE
ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves
15 Feb 2023 //
ENDPTS
ImmunityBio Announces $157 Million Financing From Investor
12 Dec 2022 //
BUSINESSWIRE
ImmunityBio looks to pull in $157M from Patrick Soon-Shiong and investor
12 Dec 2022 //
ENDPTS
Arbitrator awards $157M to Soon-Shiong`s ImmunityBio in dispute with Sorrento
05 Dec 2022 //
ENDPTS
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
17 Nov 2022 //
BUSINESSWIRE
ImmunityBio to Participate in the Jefferies London Healthcare Conference
27 Oct 2022 //
BUSINESSWIRE
ImmunityBio, aiming to hire 300 in 30 months, lays off staff
10 Oct 2022 //
FIERCEBIOTECH
ImmunityBio Announces FDA Acceptance of BLA for N-803
28 Jul 2022 //
BUSINESSWIRE
ImmunityBio Announces QUILT Trial Results for Cancers at the 2022 ASCO
06 Jun 2022 //
BUSINESSWIRE
ImmunityBio Submits BLA for N-803 Plus BCG for Patients in Bladder Cancer
23 May 2022 //
BUSINESSWIRE
ImmunityBio Announces First Participants Have Been in Lung-MAP Trial Studying
25 Apr 2022 //
BUSINESSWIRE
ImmunityBio Provides Updated Status of BLA for VesAnktiva Plus BCG
01 Apr 2022 //
BUSINESSWIRE
Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia
02 Mar 2022 //
BUSINESSWIRE
ImmunityBio Acquires Athenex’s Interest in Advanced Biotech Mfg Facility
15 Feb 2022 //
BUSINESSWIRE
ImmunityBio Shows Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure
31 Jan 2022 //
BUSINESSWIRE
ImmunityBio Presents Interim Data from Phase 2 QUILT 88 Trial
20 Jan 2022 //
TRIALSITENEWS
ImmunityBio Shows Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO
18 Jan 2022 //
BUSINESSWIRE
ImmunityBio Expands Manufacturing Capacity with State-of-Art Manufacturing Plant
12 Jan 2022 //
BUSINESSWIRE
Amyris and ImmunityBio Complete JV for Next Gen COVID-19 RNA Vaccine
03 Jan 2022 //
PRESS RELEASE
CytRx Highlights ImmunityBio`s Use of Aldoxorubicin in Various Forms of Cancer
21 Dec 2021 //
BUSINESSWIRE
ImmunityBio Completeds $470M Post-merger Financing to Fund Trials and Filings
20 Dec 2021 //
BUSINESSWIRE
Sciwind gets licensing deal with Sanofi for metabolic disease candidates
30 Nov 2021 //
ENDPTS
